Adienne 
Welcome,         Profile    Billing    Logout  
 1 Product   0 Diseases   1 Product   1 Trial   19 News 
  • ||||||||||  Review, Journal:  New investigational drugs for Steroid-Refractory Acute Graft-versus-Host disease: a review of the literature. (Pubmed Central) -  Jul 8, 2024   
    While some of these agents have shown encouraging results in early-phase trials, issues such as treatment-related toxicities and inconsistent responses in larger studies highlight the necessity for ongoing research. Current trials exploring new agents and combination therapies offer hope for fulfilling the unmet clinical needs in SR-aGVHD, potentially leading to more effective and precise treatment strategies.
  • ||||||||||  Begedina (begelomab) / Biotec Pharmacon, Adienne, Regkirona (regdanvimab) / Celltrion
    Journal:  Designing of a bispecific antibody against SARS-CoV-2 spike glycoprotein targeting human entry receptors DPP4 and ACE2. (Pubmed Central) -  Apr 12, 2022   
    Also, for blocking the primary entry receptor, hACE2, an anti-viral peptide was linked to the Fc region of BsAb that blocks the hACE2 receptor by linker cleavage inside the infected host. Thus, the designed BsAb and anti-viral peptide therapy could be a promising triumvirate way to obstruct the viral entry by blocking the receptor engagement.
  • ||||||||||  Begedina (begelomab) / Biotec, Adienne
    Clinical, Journal:  Begelomab for severe refractory dermatomyositis: A case report. (Pubmed Central) -  Mar 10, 2021   
    In conclusion, Begelomab induces over 60% responses in SR-aGvHD, including patients with severe gut and liver GvHD, having failed one or more lines of treatment. Blockade of DPP-4/CD26, which is expressed on T cells and mediates T cell activation and function, is safe and might be effective in patients with refractory DM.
  • ||||||||||  Actemra IV (tocilizumab) / Roche, JW Pharma
    Journal:  The CoV-2 outbreak: how hematologists could help to fight Covid-19. (Pubmed Central) -  Jul 1, 2020   
    We also present immunological data from gene expression experiments where TKIs resulted effective anti-inflammatory and pro-immune drugs. A possible combined treatment algorithm for COVID-19 is here proposed.
  • ||||||||||  Begedina (begelomab) / Adienne
    Trial termination, Trial primary completion date, IO biomarker:  Study of BEGEDINA (clinicaltrials.gov) -  Sep 21, 2017   
    P3,  N=36, Terminated, 
    We believe that our method would be useful for the rapid analysis of condensed phosphates in various types of fishery and processed marine food products. Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Jul 2017; Insufficient rate of accrual
  • ||||||||||  Begedina (begelomab) / Adienne
    Enrollment closed, Enrollment change, IO biomarker:  Study of BEGEDINA (clinicaltrials.gov) -  Jun 22, 2017   
    P3,  N=36, Active, not recruiting, 
    Active, not recruiting --> Terminated | Trial primary completion date: Feb 2018 --> Jul 2017; Insufficient rate of accrual Recruiting --> Active, not recruiting | N=184 --> 36
  • ||||||||||  Begedina (begelomab) / Adienne
    Enrollment open, IO biomarker:  Study of BEGEDINA (clinicaltrials.gov) -  Jun 18, 2016   
    P3,  N=184, Recruiting, 
    Recruiting --> Active, not recruiting | N=184 --> 36 Not yet recruiting --> Recruiting
  • ||||||||||  Begedina (begelomab) / Adienne
    Trial initiation date, Trial primary completion date, IO biomarker:  Study of BEGEDINA (clinicaltrials.gov) -  Jul 15, 2015   
    P3,  N=184, Not yet recruiting, 
    Not yet recruiting --> Recruiting Initiation date: Sep 2015 --> Jan 2016 | Trial primary completion date: Sep 2017 --> Feb 2018
  • ||||||||||  Begedina (begelomab) / Adienne
    New P3 trial, IO biomarker:  Study of BEGEDINA (clinicaltrials.gov) -  Apr 8, 2015   
    P3,  N=186, Not yet recruiting,